In this study, we performed multiplex immunohistochemistry (mIHC) to simultaneously detect six TIME markers, including pan-CK, CD163, CD8, forkhead box P3 (FoxP3), PD-1, and PD-L1, for the in situ labeling and defining of tumor cells, T cells, and tumor-associated macrophages (TAMs), in pre-treatment tumor tissues from 46 advanced NSCLC patients who underwent PD-1/PD-L1 blockade therapy. This evidence concerns the gene CD163 and neoplasm.